It was a brutal day for shareholders of Immutep Limited (IMMP). The Australian biotech's stock is in freefall, down a staggering 80.62% to $0.53, after the company delivered some devastating news about its most important clinical trial.
The story is about a drug trial that just didn't work out. An Independent Data Monitoring Committee has recommended that Immutep pull the plug on its TACTI-004 Phase 3 trial. This wasn't because of safety scares, but because of a planned interim futility analysis—a fancy term for checking in to see if the treatment is working well enough to justify continuing the expensive study. The answer, in this case, was no.
This trial was a big deal. It was testing Immutep's lead candidate, a drug called eftilagimod alfa (efti for short), in combination with Merck & Co. Inc.'s (MRK) blockbuster immunotherapy Keytruda and standard chemotherapy. The goal was to use this combo as a first-line therapy for patients with advanced or metastatic non-small cell lung cancer (NSCLC). The committee looked at the safety and efficacy data and essentially said, "Based on what we're seeing, this isn't likely to hit its goals." So, the company is now winding down the study in an orderly fashion and, understandably, rethinking where to spend its money next.
In a statement, CEO Marc Voigt didn't hide his disappointment. "We are disappointed by this outcome," he said, adding that the result was "unexpected" given how efti has performed in other clinical settings. It's that kind of surprise that really stings for biotech investors—when data from one study points in a promising direction, but the crucial, definitive trial tells a different story.
So, what's next for Immutep? The company says it's now going to focus on pushing forward the rest of its pipeline, which still includes efti for other types of cancer. On the financial side, they anticipate their cash runway will still extend beyond their previous guidance of the second quarter of calendar year 2027. In other words, they have time to regroup, but today's news certainly changes the game plan.
Not All Bad News for Efti
It's worth noting that this isn't the end of the road for eftilagimod alfa. The drug is still being evaluated for a variety of other solid tumors, including NSCLC in different combinations, as well as head and neck squamous cell carcinoma, soft tissue sarcoma, and breast cancer.
In fact, just last May, Immutep shared some encouraging data from a different, investigator-initiated trial called INSIGHT-003. That study looked at a triple-combo therapy for front-line NSCLC, using efti with Keytruda and a different chemotherapy regimen (carboplatin and pemetrexed). As of the data cut-off date of May 6, 2025, that combination showed a 60.8% response rate and a 90.2% disease control rate. It's a reminder that in drug development, context—the specific patient population, the exact drug combination—is everything. Success in one setting doesn't guarantee success in another, which is why Phase 3 trials like TACTI-004 are so critical.
What the Analysts Are Saying
The market's reaction has been swift and severe, but it follows some recent caution from Wall Street. The stock still carries a consensus Buy Rating, but analysts have been adjusting their views. Recent moves include:
- Citizens: Downgraded to Market Perform (Mar. 13)
- Baird: Downgraded to Neutral and lowered its price target to $1.00 (Mar. 13)
- Citizens: Had initiated coverage with a Market Outperform rating and a $10.00 target just weeks earlier (Feb. 23)
The dramatic shift in price targets tells the story of a high-risk, high-reward investment that just saw a major part of the "reward" thesis disappear.
The Bottom Line for Investors
For Immutep shareholders, Friday was a day of reckoning. The stock's 80% plunge took it to a new 52-week low of $0.53, according to market data. When a biotech's lead clinical program fails in a late-stage trial, this is often the result—a brutal repricing of the company's future prospects.
The company now faces the classic biotech pivot: reassessing its pipeline, managing its cash carefully, and trying to convince investors that there's still value beyond the failed trial. They have time, thanks to their cash runway, but they'll need compelling data from their other studies to rebuild confidence. For now, the story of efti in first-line lung cancer with this specific combo has come to a premature end.
